Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Commentary|Articles|November 5, 2024
Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?
Author(s)Hayden E. Klein
Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.
Advertisement
Advertisement
The latest report from Trilliant Health examined both the rapid adoption of glucagon-like peptide 1 (GLP-1) inhibitors for
Related to this article
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Advertisement
Advertisement